The pooled findings indicated that lipoic acid combined with valsartan could significantly reduce the level of urinary albumin and oxidative stress, enhance antioxidant capacity and mitigate renal function damages in patients with DN, and the findings proved to be helpful references for the selection of treatment drugs for DN. The gene discussed is ALB; the disease is liver dysplastic nodule.